Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Allopurinol
Drug ID BADD_D00076
Description Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints [A175942]. This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals [A175942]. Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout [A36705]. It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677].
Indications and Usage For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy, with or without the symptoms of gout, as well as chemotherapy-induced hyperuricemia and recurrent renal calculi.
Marketing Status Prescription; Discontinued
ATC Code M04AA01
DrugBank ID DB00437
KEGG ID D00224
MeSH ID D000493
PubChem ID 135401907
TTD Drug ID D04KYY
NDC Product Code 50268-063; 49711-0113; 16714-041; 0603-2116; 14445-001; 69967-008; 55700-879; 50090-4662; 23155-694; 53489-156; 0591-5544; 0904-7041; 0378-0181; 55700-935; 66267-665; 61919-748; 50090-5194; 67457-187; 51079-206; 63739-796; 43063-976; 68083-380; 23155-693; 70518-1678; 71335-0112; 17351-0041; 55700-540; 67296-1265; 71610-253; 63629-2113; 51079-205; 50268-064; 29300-350; 68071-2660; 70934-072; 55700-947; 55154-5534; 50090-0044; 70934-389; 61919-471; 55111-730; 68071-1805; 71610-197; 70518-3289; 70710-1210; 63629-1781; 58118-1156; 67296-1314; 49452-0008; 70518-1806; 65015-606; 16729-135; 0904-6571; 63552-151; 70771-1127; 55154-2338; 62584-988; 70199-016; 70710-1209; 43353-088; 55154-7892; 16729-134; 0615-8385; 0591-5543; 68108-0212; 71205-208; 63629-8020; 43063-975; 71335-0467; 70771-1126; 68071-2616; 63187-240; 53002-4821; 36974-0018; 50090-2544; 69967-009; 70934-504; 63629-7908; 0615-8321; 51927-0070; 71610-064; 63629-2111; 50090-5168; 71610-194; 60760-134; 53002-4820; 65219-380; 70934-295; 65977-0124; 43063-793; 70199-015; 67457-978; 71610-231; 67544-736; 50090-3760; 43063-079; 71205-377; 62584-713; 71205-049; 50090-4663; 63629-1675; 63552-150; 0378-0137; 16714-042; 16714-577; 55154-7981; 16714-576; 43063-935; 29300-349; 70934-209; 70518-0451; 55289-010; 43353-186; 0603-2115; 55154-5454; 43063-774; 71335-1656; 55111-729; 60760-139; 0904-6572; 63629-2112; 70934-681; 43063-934; 50090-3758; 63739-410; 57451-1166; 60429-180; 66064-2100; 51927-1915; 66267-224; 68788-7542; 53489-157; 63187-463; 70518-1573; 68788-7383
Synonyms Allopurinol | Uribenz | Allopurin | Allorin | Allpargin | Allural | Pan Quimica | Apulonga | Apurin | Atisuril | Bleminol | Caplenal | Capurate | Cellidrin | Embarin | Suspendol | Foligan | Hamarin | Lopurin | Lysuron | Jenapurinol | Milurit | Milurite | Novopurol | Uripurinol | Urosin | Urtias | Xanthomax | Uridocid | Xanturic | Zygout | Zyloprim | Zyloric | Pureduct | Purinol | Progout | Remid | Rimapurinol | Roucol | Tipuric | Allohexal | Allohexan | Alloprin
Chemical Information
Molecular Formula C5H4N4O
CAS Registry Number 315-30-0
SMILES C1=NNC2=C1C(=O)NC=N2
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood pressure increased13.14.03.005--Not Available
Blood triglycerides increased13.12.03.0010.000132%Not Available
Blood urea increased13.13.01.0060.000527%Not Available
Body temperature increased13.15.01.0010.000264%Not Available
Bone pain15.02.01.001--
Bowen's disease16.03.02.004; 23.08.02.0040.000395%Not Available
Bradycardia02.03.02.0020.000593%Not Available
Brain herniation12.01.10.001; 17.11.01.0020.000034%Not Available
Bronchitis11.01.09.001; 22.07.01.001--
Bronchospasm10.01.03.012; 22.03.01.004--
C-reactive protein increased13.09.01.0070.000659%Not Available
Calculus urinary20.04.02.0010.000198%Not Available
Capillary leak syndrome08.01.07.012; 24.06.03.0010.000034%
Cardiac arrest02.03.04.0010.000258%
Cardiac failure02.05.01.0010.000258%
Cardiac failure acute02.05.01.0050.000103%Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cardio-respiratory arrest02.03.04.002; 22.02.06.007--Not Available
Cardiogenic shock02.05.01.003; 24.06.02.006--Not Available
Cardiomegaly02.04.02.0010.000086%Not Available
Cardiomyopathy02.04.01.0010.000052%Not Available
Cardiovascular disorder02.01.01.001; 24.03.02.009--Not Available
Cataract06.06.01.001--
Cellulitis11.02.01.001; 23.09.01.0010.000329%Not Available
Cerebral haemorrhage17.08.01.003; 24.07.04.001--Not Available
Cerebral infarction17.08.01.004; 24.04.06.0020.000461%Not Available
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Cheilitis07.05.01.001; 23.03.03.0250.000198%
Chest discomfort02.02.02.009; 08.01.08.019; 22.02.08.001--Not Available
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.003--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 22 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene